Keros Therapeutics News

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)

TipRanksMay 10 01:20 ET

Keros Therapeutics Analyst Ratings

BenzingaMay 9 07:55 ET

HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target

BenzingaMay 9 07:56 ET

Buy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS Treatment

TipRanksMay 9 06:36 ET

Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Keros Therapeutics (KROS)

TipRanksMay 9 06:20 ET

Buy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial Health

TipRanksMay 9 05:19 ET

Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012

TipRanksMar 29 03:05 ET

Keros Therapeutics Analyst Ratings

BenzingaMar 27 12:47 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)

TipRanksMar 27 08:40 ET

Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)

TipRanksMar 27 07:05 ET

Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment

TipRanksMar 19 01:37 ET

Keros Therapeutics Analyst Ratings

BenzingaMar 13 13:22 ET

Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)

TipRanksMar 13 07:35 ET

Keros Therapeutics (KROS) Gets a Buy From Truist Financial

TipRanksMar 6 08:06 ET

Keros Therapeutics Analyst Ratings

BenzingaMar 1 06:37 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)

TipRanksMar 1 06:20 ET

Buy Rating Justified by Keros Therapeutics' Clinical Advancements and Strong Financial Position

TipRanksFeb 29 06:48 ET

Keros Therapeutics Coverage Initiated at William Blair With Outperform Rating, $81 Stock Price Target

InvestingFeb 21 07:48 ET

Jefferies Analyst Issues Buy Rating for Keros Therapeutics, Citing Strong Pipeline and Financial Stability

TipRanksJan 23 08:15 ET

Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)

TipRanksJan 9 07:37 ET